Mutant/mutation
The mutant expresses a well-defined Trypanosoma cruzi-derived, H-2Kb-restricted CD8+ T cell epitope (ANYNFTLV, from TSSA) fused to GFP under control of the P. berghei hsp70 promoter.

Protein (function)

Phenotypee
The mutant has been used to analyse blood-stage specific CD8+ T cells in protective immunity taking advantage of the H-2Kb-restricted, T. cruzi-derived CD8+ T cell-inducing  epitope, ANYNFTLV

Additional information
The lack of MHC molecules on red blood cells (RBCs) has led to questions regarding the immunological function of CD8+ T cells against malarial blood-stage (MBS). However, several recent reports contradicting with this concept have suggested that they play an important role in the course of MBS infection. The present study generated genetically engineered murine malaria, P. yoelii, which expresses a well-defined T. cruzi-derived, H-2Kb-restricted CD8+ T cell epitope, ANYNFTLV. Prime/boost vaccination by the use of recombinant adenovirus and recombinant modified vaccinia virus Ankara (MVA), which induced an enhanced number of ANYNFTLV-specific CD8+ T cells, failed to prevent a pathological outcome to occur upon ANYNFTLV-expressing murine MBS infection.
In contrast, the pre-infection of mice with T. cruzi, which intrinsically bears the same CD8+ T cell epitope significantly improved the survival of ANYNFTLV-expressing malaria-infected mice but not that of control malaria-infected ones. This protective effect was abrogated by the use of a CD8+ T cell-depleting monoclonal antibody.

Three other mutants were generated in this study: pyDH7TSSA (expressing theTSSA epitope not fused to GFP under the control of the hsp70  promoter) and two control mutants named pyDH7 (only the hsp70  promoter) and pyDH7GFP (only GFP under the control of the hsp70  promoter). These mutants are not included in RMgmDB.

Other mutants